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More than 45000 articles in the PubMed database and around 3200 studies registered in ClinicalTrials.gov, of
which greater than half are clinical trials, are the result of ongoing and relentless research into the global
pandemic nature of an acute respiratory disease caused by the severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2), which made its initial appearance in December 2019 in China. As of 28 August 2020, the
total confirmed cases of coronavirus disease 2019 (COVID-19) surpasses 24.5 million, with more than 830
000 global deaths [1]. An estimated 40% to 45% of persons infected with SARS-CoV-2 will remain
asymptomatic, but they can transmit the virus to others for an extended period, perhaps longer than 14 days
[2]. The primary presentation of symptomatic infection is that of an influenza-like illness or viral pneumonia,
with about 20% of these patients developing severe or critical manifestations [3].
Pleural disease encompasses pleural effusion and pneumothorax. In the context of COVID-19, both are
considered to be so atypical or unusual that they should compel clinicians to seek alternative diagnoses
[4]. This might be challenged by new observations, including those of MARTINELLI et al. [5] in this issue of
the European Respiratory Journal. According to several systematic reviews [6–10], pooled prevalences of
pleural thickening and pleural effusions on computed tomography (CT) scans are approximately 38% and
5%, respectively (table 1). However, the frequency of pleural effusions varies with age and disease severity.
For example, in an Iranian study of 552 COVID-19 symptomatic patients, CT detected pleural effusions in
7.6% of cases overall; a percentage which was significantly higher in those over 50 years of age versus
under (10% versus 5.2%; p=0.037) [11]. Additionally, in a multicentre study of 476 patients with
COVID-19, more patients in the critical than in the severe or moderate disease groups had pleural
effusions on CT images at admission (18%, 7.4% and 3.1%, respectively; p<0.001) [12]. It may be argued
that most, if not all, of these pleural effusions may be secondary to comorbid conditions rather than being
directly related to the viral infection. About half of COVID-19 patients have comorbidities [12, 13],
including pre-existing cardiovascular diseases (12.6%) or heart failure (6.5%) [14]. Moreover, more than
25% of infected patients exhibit myocardial injury of potential inflammatory pathogenesis (a cause of
impaired cardiac function) as demonstrated by elevation of troponin T levels [14] and, at least 20%
develop heart failure during disease course [15]. On the other hand, the incidence of pulmonary embolism
was 8.3% among 1240 infected patients who were subjected to a CT pulmonary angiography [16]. And
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both, heart failure and pulmonary embolism [17], in addition to respiratory co-infections [18], are
well-recognised aetiologies of pleural effusions. Despite the fact that a certain number of patients may have
pleural effusions derived from the preceding causes, SARS-CoV-2 undoubtedly gives rise to fluid
formation since it has been detected by RT-PCR in pleural fluid specimens [19, 20].
Non-COVID-19 viral pneumonias share many CT features with COVID-19, except for a higher prevalence
of pleural effusions. In a systematic review of 33 studies, comprising 1911 patients equally distributed
between COVID-19 and non-COVID-19 viral pneumonias (mainly influenza A and adenovirus), pleural
effusions were observed in 3% and 25% of the cases, respectively [21]. Regarding other beta-coronaviruses,
very few small series on CT appearances have been reported and, therefore, firm conclusions cannot be
drawn. The true prevalence of pleural effusions in SARS-CoV-1 infections is conflicting, ranging from two
(6.8%) of 29 patients [22] to seven (26%) of 27 [23] in two different reports. In one study of 55 patients
infected with Middle East respiratory syndrome coronavirus (MERS-CoV), pleural effusions were visible in
the chest radiographs of 17 (31%) and represented a poor prognostic indicator [24]. A previous
retrospective study by the same authors found that nine (60%) of 15 patients with MERS-CoV had pleural
effusions on CT [25].
MARTINELLI et al. [5] describe the occurrence of pneumothorax and pneumomediastinum as important,
though infrequent, clinical features of COVID-19 [5]. In their retrospective study, clinical details were
reported for 60 cases of pneumothoraces that occurred among an estimated 6574 COVID-19 admissions
across multiple centres in the UK. This represents an incidence of 0.91%, which is consistent with
previous observations. For instance, in a series of 92 deceased patients with COVID-19, one death was
attributed to pneumothorax (1.1%) [26]. Similarly, this complication was described in one (1%) of 99
patients by others [27], while seven spontaneous air leaks (five pneumomediastinum and two
pneumothoraces) were found as part of 976 COVID-19 cases (0.7%) in an American institution [28].
Notably, of the 60 pneumothorax patients reported in this issue, 75% were older than 50 years, and more
than half had never smoked, which is difficult to reconcile with the primary spontaneous variety [5]. Also,
one-third of the patients were not submitted to invasive or non-invasive mechanical ventilatory support at
the time of diagnosis, thus ruling out iatrogenic causes [5]. Consequently, the existence of a true secondary
spontaneous pneumothorax due to SARS-CoV-2 should be admitted, as in other respiratory infections.
For example, about 1% of patients with active tuberculosis [29], up to 9% of those with Pneumocystis
jirovecci pneumonia [30], and 1.7% of SARS-CoV-1 infected subjects [31] may develop pneumothorax. As
far as MERS-CoV is concerned, the clinical course of nine (16%) of 55 patients complicated with
pneumothorax, but all of them were intubated and so, the contribution of barotrauma and/or volutrauma
was probably meaningful [24]. The pathological basis for pneumothorax in non-ventilated COVID-19
patients is uncertain. While not usually seen in autopsy reports, lung cavitation and/or cystic lesions
unrelated to the use of mechanical ventilation can occur in COVID-19 [32]. The severe cough that may be
associated with COVID-19 and the corresponding increase in intrapulmonary pressure may precipitate the
rupture of viral-induced damaged alveoli of peripheral location and pneumothorax formation.
Pneumothorax should be managed following standard guidelines, wearing personal protective equipment
for chest tube placement and considering strategies to minimise droplet exposure via the chest drain
circuit (e.g. connecting anti-viral filters on suction ports or adding bleach to the water seal chamber) [33].
Many of the preceding statements for pneumothorax in the setting of SARS-CoV-2 infection hold true for
pneumomediastinum. It is a rare entity, frequently related to mechanical ventilation, which may also
appear spontaneously in the context of respiratory infections, like influenza [34]. In the series reported by
MARTINELLI et al. [5], only 1 (9%) of 11 pneumomediastinum cases was labelled as spontaneous [5]. It
appears, however, to be a more frequent characteristic feature of SARS-CoV-1 infection, with two separate
TABLE 1 Prevalence of pleural effusions and thickening on chest computed tomography
imaging of adult coronavirus disease 2019 patients: relevant systematic reviews
Systematic review Studies n Patients n Pleural thickening# Pleural effusion
ADAMS et al. [6] 28 3466 34.7% 5.2%
BAO et al. [7] 13 2738 52.5% 5.8%
OJHA et al. [8] 45 4410 41.7% 5.0%
ZHENG et al. [9] 15 2150 ND 3.0%
ZHU et al. [10] 34 4121 27.1% 5.3%
#: pleural thickening adjacent to underlying lung involvement. ND: not done.
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series of 75 and 112 patients reporting a 12% incidence of this complication [35, 36]. Pneumothorax and
pneumomediastinum, in addition to pulmonary embolism or progression of the primary disease, should
be considered in any COVID-19 patient with acute respiratory deterioration.
In brief, there is direct evidence that SARS-CoV-2 infection produces pleural effusion, and circumstantial
evidence that it may cause secondary spontaneous pneumothorax and pneumomediastinum. Although
alternative explanations primarily related to comorbidities and iatrogenic effects should always be sought,
the Latin aphorism “ubi fumus, ibi ignis” (where there’s smoke, there’s fire) is perfectly applicable to
pleural involvement in the setting of COVID-19.
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